AvenanthramideThe interesting thing about the avenanthramide pill is that there is already human clinical data that could be built upon thereby reducing risk. CSCI isn't going in totally blimd. There was a human study of avenanthramide in a smoothie, for instance. 90mg per day resulted in a significant decrease in VCAM-1. CSCI may be able to dose twice per day at 240mg or higher for a daily dose of avenanthramide multiples higher than the smoothie study.
VCAM-1 (Vascular Cell Adhesion Molecule-1) is increasingly recognized as a promising drug target due to its critical role in inflammation, monocyte recruitment, and vascular damage, particularly in conditions such as atherosclerosis, diabetes, hypertension, and brain metastases. Avenanthramide can affect a number of biomarkers. Based on the abstract provided and related studies, Ceapro's pharma-grade avenanthramide (AVA) administered at two doses per day (240 mg per dose) could potentially have a significant effect on reducing VCAM-1 levels, a biomarker of inflammation. Here's an analysis: - Pilot Study Results: In the pilot study mentioned in the abstract, 90 mg of AV-enriched oat bran daily reduced VCAM-1 concentrations by 13% at 4 weeks and 10% at 8 weeks in subjects with elevated CRP levels. This suggests that even relatively low doses of AV can reduce VCAM-1 levels .
- Higher Doses: Ceapro's dosing regimen (480 mg daily) is substantially higher than the 90 mg used in the study. Given that AV effects on inflammation are dose-dependent, as observed in other studies, it is reasonable to expect a more pronounced reduction in VCAM-1 levels at this higher dose .
- Mechanistic Evidence: Avenanthramides have been shown to inhibit the expression of adhesion molecules like VCAM-1 in vitro and in vivo, likely through their anti-inflammatory and antioxidant properties . This supports their potential for greater efficacy at higher doses.
Although exact reductions cannot be directly extrapolated without clinical data specific to the 480 mg/day dose, a significant improvement beyond the 10–13% reduction observed with 90 mg/day is plausible based on dose-response trends.